

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **VOLUNTARY ANNOUNCEMENT CLARIFICATION**

This announcement is issued by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to (i) the Company’s voluntary announcement regarding the unusual price movements (the “**Unusual Price Movements**”) of the shares of the Company (the “**Shares**”) published at noon on November 14, 2023; and (ii) the Company’s inside information announcement (the “**Inside Information Announcement**”) regarding updates (the “**Clinical Updates**”) in relation to a phase III clinical trial of KN046 for the treatment of advanced pancreatic ductal adenocarcinoma (“**KN046-303**”) published after trading hours on the same day.

The Company has been made aware of certain media reports (the “**Media Reports**”) claiming that the inside information regarding Clinical Updates was released prior to the disclosure in the Inside Information Announcement, resulting in the Unusual Price Movements.

The Company has promptly taken steps in response to the Unusual Price Movements and Media Reports including, among others, (i) communicating with the competent authority promptly, (ii) conducting internal investigations on, in particular, the confidentiality and compliance of the relevant clinical data management process, and (iii) engaging independent investigator to investigate relevant external parties involved in KN046-303.

The Company would like to make the following clarifications:

1. The closed session (the “**iDMC Closed Session**”) of the independent data monitoring committee (the “**iDMC**”) regarding the interim analysis (the “**Interim Analysis**”) of KN046-303 was convened between 15:00 and 16:00 on November 14, 2023. Under the organization of the independent third party institutions, the interim analysis of the unblinding data of KN046-303 was reviewed and concluded independently by the iDMC, which was highly confidential without any involvement of the Company.
2. The Company received the conclusion of the Interim Analysis from the iDMC Closed Session after trading hours on November 14, 2023. Upon receipt of the conclusions, the Company promptly prepared and published the Inside Information Announcement on the websites of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.alphamabonc.com](http://www.alphamabonc.com)).

3. To the best knowledge, information, and belief of the Company after making reasonable enquiries and internal investigations, the Company confirms that (i) the Company does not have any access to the unblinding data of KN046-303, (ii) the Company is not aware of any evidence of unlawful disclosure, intentionally or recklessly, of the Clinical Updates of KN046-303 by the employees of the Group prior to the publication of the Inside Information Announcement, and (iii) there was no dealing in the Shares by the Directors, senior management or key employees of the Company from November 1, 2023 to November 14, 2023.

The Company is committed to maintaining transparent and timely communication with the public market, and will announce any material information in accordance with applicable laws and listing rules. The Company also wishes to remind its shareholders and potential investors to refer to announcements published on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company's website ([www.alphamabonc.com](http://www.alphamabonc.com)) for information about the Group.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, November 24, 2023

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the board of the Directors and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*